Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy
Table 4
Secondary outcomes and IOP.
IVC
IVR
IVTA
value
Vitreous clear-up time (days)
(Mean ± SD)
6.10 ± 1.52
6.32 ± 1.57
11.11 ± 2.38
0.66, <0.01, <0.01
Intraoperative bleeding (cases, %)
2 (10.0)
3 (15.8)
9 (47.4)
0.602, 0.010, 0.04
Postoperative bleeding (cases, %)
1 (5.0)
1 (5.3)
3 (15.8)
0.971, 0.287, 0.305
PRP completion rate (cases, %)
11 (55.0)
10 (52.6)
6 (31.6)
0.886, 0.147, 0.199
Reoperation probability (cases, %)
1 (5.0)
1 (5.3)
2 (10.5)
0.971, 0.534, 0.560
IOP increase (case, %)
3 (15.0)
2 (10.5)
9 (47.4)
0.684, 0.031, 0.011
value of IVC versus IVR, IVC versus IVTA, and IVR versus IVTA.
